Polyinosinic/polycytidylic acid-mediated changes in maternal and fetal disposition of lopinavir in rats

Drug Metabolism and Disposition

Volumn 43, Issue 7, 2015, Pages 951-957

  Petrovic, Vanja ^a   Piquette Miller, Micheline ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER B1A; ABC TRANSPORTER B1B; GAMMA INTERFERON; LOPINAVIR; MESSENGER RNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 1; POLYINOSINIC POLYCYTIDYLIC ACID; UNCLASSIFIED DRUG; CYP3A2 PROTEIN, RAT; CYTOCHROME P450 3A; CYTOKINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTERFERON INDUCING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG TRANSPORT; ELIMINATION RATE CONSTANT; FEMALE; FETUS; GENE EXPRESSION; INTERFERON INDUCTION; LIQUID CHROMATOGRAPHY; MATERNAL BLOOD; NONHUMAN; PLACENTA TISSUE; PLASMA PROTEIN BINDING; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY; VOLUME OF DISTRIBUTION; ANIMAL; DRUG INTERACTION; LIVER; METABOLISM; PLACENTA; PREGNANCY; SPRAGUE DAWLEY RAT;

HUMAN IMMUNODEFICIENCY VIRUS; RATTUS;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CYTOCHROME P-450 CYP3A; CYTOKINES; DRUG INTERACTIONS; FEMALE; FETUS; HIV PROTEASE INHIBITORS; INTERFERON INDUCERS; INTERFERON-GAMMA; LIVER; LOPINAVIR; PLACENTA; POLY I-C; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84940367439     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.062315     Document Type: Article

References (38)

1. Agarwal S, Pal D, and Mitra AK (2007) Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int J Pharm 339:139-147.
2. Anger GJ and Piquette-Miller M (2008) Pharmacokinetic studies in pregnant women. Clin Pharmacol Ther 83:184-187.
3. Anger GJ and Piquette-Miller M (2011) Mechanisms of reduced maternal and fetal lopinavir exposure in a rat model of gestational diabetes. Drug Metab Dispos 39:1850-1859.
4. Aweeka FT, Stek A, Best B.M., Hu C., Holland D, Hermes A, Burchett S.K., Read J., Mirochnick M, and Capparelli EV; International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1026s Protocol Team (2010) Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med 11:232-238.
5. Bailer AJ (1988) Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16:303-309.
6. Benet LZ and Cummins CL (2001) The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 50 (Suppl 1):S3-S11.
7. Chandwani A and Shuter J (2008) Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag 4:1023-1033.
8. Fortier M-E, Kent S., Ashdown H, Poole S, Boksa P., and Luheshi GN (2004) The viral mimic, polyinosinic: polycytidylic acid, induces fever in rats via an interleukin-1-dependent mechanism. Am J Physiol Regul Integr Comp Physiol 287:R759-R766.
9. Gingelmaier A, Kurowski M, Kästner R, Eberle J., Mylonas I, Belohradsky BH, Friese K, and Grubert TA (2006) Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 20:1737-1743.
10. Gulati A, Boudinot FD, and Gerk PM (2009) Binding of lopinavir to human alpha1-acid gly-coprotein and serum albumin. Drug Metab Dispos 37:1572-1575.
11. Hartmann G, Vassileva V, and Piquette-Miller M (2005) Impact of endotoxin-induced changes in P-glycoprotein expression on disposition of doxorubicin in mice. Drug Metab Dispos 33: 820-828.
12. Hochepied T, Berger FG, Baumann H, and Libert C (2003) Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev 14:25-34.
13. Janneh O, Jones E, Chandler B., Owen A, and Khoo SH (2007) Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 60: 987-993.
14. Kis O, Robillard K, Chan GNY, and Bendayan R (2010) The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 31:22-35.
15. Knickle LC, Spencer DF, and Renton KW (1992) The suppression of hepatic cytochrome P4504A mRNA mediated by the interferon inducer polyinosinic acid.polycytidylic acid. Bio-chem Pharmacol 44:604-608.
16. Kumar GN, Jayanti V, Lee R.D., Whittern DN, Uchic J, Thomas S, Johnson P., Grabowski B, Sham H, and Betebenner D, et al. (1999) In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification. Drug Metab Dispos 27:86-91.
17. Kumar GN, Jayanti VK, Johnson M.K., Uchic J., Thomas S, Lee RD, Grabowski B.A., Sham HL, Kempf DJ, and Denissen JF, et al. (2004) Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm Res 21:1622-1630.
18. Laethem ME, Belpaire FM, Wijnant P, Rosseel M.T., and Bogaert MG (1994) Influence of endotoxin on the stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil in the rat. Chirality 6:405-410.
19. Lambert JS, Else LJ, Jackson V, Breiden J., Gibbons S, Dickinson L, Back D.J., Brennan M., Connor EO, and Boyle N, et al. (2011) Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Med 12:166-173.
20. Morgan ET (1997) Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 29:1129-1188.
21. Morgan ET, Goralski KB, Piquette-Miller M, Renton K.W., Robertson GR, Chaluvadi MR, Charles KA, Clarke S.J., Kacevska M., and Liddle C, et al. (2008) Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 36:205-216.
22. Murai-Kushiya M., Okada S, Kimura T., and Hasegawa R (1993) Effects of turpentine oil pre-treatment on beta-blocker pharmacokinetic parameters in rats. J Pharm Pharmacol 45: 836-838.
23. Ofotokun I, Lennox JL, Eaton M.E., Ritchie JC, Easley KA, Masalovich SE, Long M.C., and Acosta EP (2011) Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure. J Clin Pharmacol 51:1539-1548.
24. Petropoulos S, Kalabis GM, Gibb W, and Matthews SG (2007) Functional changes of mouse placental multidrug resistance phosphoglycoprotein (ABCB1) with advancing gestation and regulation by progesterone. Reprod Sci 14:321-328.
25. Petrovic V and Piquette-Miller M (2010) Impact of polyinosinic/polycytidylic acid on placental and hepatobiliary drug transporters in pregnant rats. Drug Metab Dispos 38:1760-1766.
26. Petrovic V, Teng S, and Piquette-Miller M (2007) Regulation of drug transporters during infection and inflammation. Mol Interv 7:99-111.
27. Petrovic V, Wang J-H, and Piquette-Miller M (2008) Effect of endotoxin on the expression of placental drug transporters and glyburide disposition in pregnant rats. Drug Metab Dispos 36: 1944-1950.
28. Renton KW (2001) Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 92:147-163.
29. Romero R, Gotsch F, Pineles B., and Kusanovic JP (2007) Inflammation in pregnancy: its roles in reproductive physiology, obstetrical complications, and fetal injury. Nutr Rev 65:S194-S202.
30. Schreiber G, Tsykin A, Aldred A.R., Thomas T., Fung WP, Dickson PW, Cole T, Birch H., De Jong FA, and Milland J (1989) The acute phase response in the rodent. Ann N Y Acad Sci 557:61-85, discussion 85-86
31. van Heeswijk RPG, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Phillips EJ, and Cameron DW (2004) The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther 76:588-597.
32. van Waterschoot RAB, ter Heine R, Wagenaar E, van der Kruijssen CMM, Rooswinkel RW, Huitema ADR, Beijnen JH, and Schinkel AH (2010) Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the phar-macokinetics of lopinavir. Br J Pharmacol 160:1224-1233.
33. Wang JH, Scollard DA, Teng S, Reilly R.M., and Piquette-Miller M (2005) Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging. J Nucl Med 46:1537-1545.
34. Wang PG, Wei JS, Kim G, Chang M., and El-Shourbagy T (2006) Validation and application of a high-performance liquid chromatography-tandem mass spectrometric method for simultaneous quantification of lopinavir and ritonavir in human plasma using semi-automated 96-well liquid-liquid extraction. J Chromatogr A 1130:302-307.
35. Watts DH (2006) Treating HIV during pregnancy: an update on safety issues. Drug Saf 29: 467-490.
36. Watts DH, Balasubramanian R, Maupin R.T., Jr, Delke I, Dorenbaum A, Fiore S, Newell ML, Delfraissy JF, Gelber RD, and Mofenson LM, et al. PACTG 316 Study Team (2004) Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol 190:506-516.
37. Wyen C, Fuhr U, Frank D., Aarnoutse RE, Klaassen T, Lazar A, Seeringer A., Doroshyenko O, Kirchheiner JC, and Abdulrazik F, et al. (2008) Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 84:75-82.
38. Zhou L, Naraharisetti SB, Wang H, Unadkat J.D., Hebert MF, and Mao Q (2008) The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol Pharmacol 73: 949-959.